Chinese Journal of Pharmaceuticals
|
2022, 53(7): 1056-1061
• Pharmaceutical Management & Information •
Explaination of New Guideline for Post-approval Changes to Chemical Drug in Combination with the Post-approval Change Managements in China, the United States and Europe
Full
Affiliations
- Center for Drug Evaluation, National Medical Products Administration, Beijing 100022
Published: 2022-07-10
doi: 10.16522/j.cnki.cjph.2022.07.020
Outline
张保梅, 陆骁骏.
结合中美欧的上市后变更管理制度浅谈我国新版上市后化药变更指导原则.
中国医药工业杂志,
2022
, 53
(7)
: 1056
-1061
.
DOI: 10.16522/j.cnki.cjph.2022.07.020
Baomei ZHANG, Xiaojun LU.
Explaination of New Guideline for Post-approval Changes to Chemical Drug in Combination with the Post-approval Change Managements in China, the United States and Europe[J].
Chinese Journal of Pharmaceuticals,
2022
, 53
(7)
: 1056
-1061
.
DOI: 10.16522/j.cnki.cjph.2022.07.020
Year 2022 volume 53 Issue 7
81
14
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2022.07.020
- Receive Date:2021-08-27
- Online Date:2026-11-12
- Published:2022-07-10